Market Valuation & Earnings Multiples
Market capitalization, P/E ratios, and enterprise value
Market Cap3.45B
Enterprise Value3.43B
ARQT
(NASDAQ)Arcutis Biotherapeutics, Inc.
$26.66-- (--)
Loading... - Market loading
Arcutis Biotherapeutics (ARQT) Key Statistics & Financial Metrics
Complete stock analysis with 40+ metrics: valuation ratios, profitability margins, financial health indicators, and dividend data.
Stock Valuation Metrics
Market value, earnings multiples, and pricing ratios
Price-Based Ratios
Valuation ratios based on stock price
Price/Sales (ttm)8.30
Forward Price/Sales4.25
Price/Book (mrq)18.19
Price/Tangible Book (mrq)19.66
Price/FCF (ttm)128.13
Price/OCF (ttm)127.76
Enterprise Value Ratios
EV-based valuation multiples
EV/Revenue8.25
EV/Earnings-1442.47
EV/EBITDA265.03
EV/EBIT-488.36
EV/FCF127.33
Stock Price
Current price, 52-week range, and moving averages
Current Price$26.66
1-Day Change1.72%
52-Week High$31.77
52-Week Low$13.06
52-Week Change92.91%
YTD Change-8.07%
1-Year Change85.14%
50-Day MA$22.80
200-Day MA$24.05
Avg Volume (30 day)2.02M
Share Statistics
Outstanding shares, float, and per-share metrics
Shares Outstanding129.37M
Book Value per Share$1.47
Net Cash per Share$0.17
FCF per Share$0.21
Analyst Price Targets & Consensus
Wall Street analyst ratings and 12-month price targets (90 days)
Price Target$34.83
Target Upside/Downside30.65%
Analyst ConsensusBuy
Analyst Count6
Profitability & Financial Performance
Profit margins, return metrics, and earnings analysis
Profit Margins
Profitability margins across income statement
Gross Margin90.94%
EBITDA Margin (ttm)3.11%
EBIT Margin (ttm)-1.69%
Operating Margin (ttm)0.77%
Pretax Margin (ttm)-0.33%
Profit Margin (ttm)-0.57%
FCF Margin (ttm)6.48%
Return on Investment Metrics
ROE, ROA, ROIC, and capital efficiency ratios
Return on Equity (ttm)-1.25%
Return on Assets (ttm)-0.52%
Return on Invested Capital (ttm)-3.30%
Return on Capital Employed (ttm)-2.36%
Income Statement (TTM)
Trailing twelve months revenue and earnings
Revenue415.62M
Gross Profit377.98M
Operating Income3.21M
Pretax Income-1.39M
Net Income-2.38M
EBITDA12.93M
EBIT-7.02M
Diluted EPS$-0.02
Cash Flow (TTM)
Operating cash flow and free cash flow metrics
Operating Cash Flow26.99M
Capital Expenditures78.00K
Free Cash Flow26.92M
Growth Rates (YoY)
Year-over-year growth metrics
Revenue Growth95.29%
Financial Health & Dividends
Balance sheet analysis, debt ratios, and dividend metrics
Assets & Cash
Total assets and cash positions
Total Assets (mrq)460.00M
Cash & Securities (mrq)34.76M
Net Cash (mrq)21.56M
Net Cash per Share$0.17
Debt & Liabilities
Liabilities, debt, equity, and working capital
Total Debt (mrq)13.20M
Working Capital (mrq)274.85M
Total Equity (mrq)189.65M
Book Value per Share$1.47
Liquidity & Leverage
Liquidity, leverage, and debt coverage ratios
Current Ratio (mrq)2.68
Quick Ratio (mrq)2.46
Debt/Equity (mrq)0.07
Debt/EBITDA (ttm)1.02
Debt/FCF (ttm)0.49
Dividend History & Payout Analysis
Dividend yield, payout ratios, and growth metrics
Dividend per Share (TTM)$0.00
Dividend Yield0.00%
Yield Metrics
Earnings, FCF, buyback, and shareholder yields
Earnings Yield-0.07%
FCF Yield0.78%
Buyback Yield-0.18%
Total Shareholder Yield-0.18%
Financial Health Scores
Risk assessment and quality metrics
Altman Z-Score-3.59
Piotroski F-Score3/9
Frequently Asked Questions About Arcutis Biotherapeutics Statistics
What are the key financial metrics for ARQT?
Arcutis Biotherapeutics, Inc. (ARQT) statistics include 40+ financial metrics organized into valuation ratios (P/E, P/S, P/B, PEG), profitability margins (gross, operating, net), return metrics (ROE, ROA, ROIC), and financial health indicators. These are updated regularly based on the latest filings and market data.
What is ARQT's valuation analysis?
The valuation section covers market capitalization, earnings multiples like trailing and forward P/E, price-based ratios (P/S, P/B, Price/FCF), and enterprise value ratios (EV/EBITDA, EV/Revenue, EV/FCF). Compare these against sector averages to assess whether Arcutis Biotherapeutics is overvalued or undervalued.
How do I read ARQT's profitability ratios?
Arcutis Biotherapeutics's profitability is measured through profit margins (gross, EBITDA, operating, net) and return metrics (ROE, ROA, ROIC, ROCE). Higher margins indicate better cost control, while higher returns show efficient capital deployment. The income statement and cash flow sections provide the underlying revenue and earnings data.
What do ARQT's debt ratios indicate?
The financial health section shows Arcutis Biotherapeutics's leverage through debt-to-equity, debt-to-assets, debt-to-EBITDA, and debt-to-FCF ratios, plus liquidity via the current and quick ratios. Lower debt ratios and higher liquidity ratios generally indicate stronger financial stability and lower default risk.
What is ARQT's dividend analysis?
The dividend section covers Arcutis Biotherapeutics's dividend yield, payout ratios (earnings-based and FCF-based), year-over-year dividend growth, years of consecutive growth, ex-dividend and pay dates, and payment frequency. The yield metrics section also includes earnings yield, FCF yield, buyback yield, and total shareholder yield.